Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma

Background: Lung cancer is a complex disease with many subtypes. However, histochemical characteristics, and genetic mutation determinations are contributing to better define therapeutic targets and new drugs. Although this guarantees patients the possibility of obtaining tailored treatment, it make...

Full description

Bibliographic Details
Main Authors: Caterina Gianni, Giuseppe Bronte, Angelo Delmonte, Marco Angelo Burgio, Kalliopi Andrikou, Manlio Monti, Cecilia Menna, Giovanni Luca Frassineti, Lucio Crinò
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Pharmacology
Subjects:
non-small cell lung cancer
pembrolizumab
osimertinib
stevens johnson syndrome
liver toxicity
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.672233/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.672233/full

Similar Items